MONMOUTH JUNCTION, N.J., May 24 /PRNewswire/ -- Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No.

Bayer HealthCare and Nektar Therapeutics have reported positive preliminary Phase II data on their drug-device combination Amikacin Inhale.

TORONTO and BERLIN, May 19 /PRNewswire-FirstCall/ -- Bayer HealthCare together with Nektar Therapeutics , today presented positive preliminary Phase II data on their unique drug-device combination Amikacin Inhale at the American Thoracic Society (ATS) annual meeting.

MONMOUTH JUNCTION, N.J., March 31 /PRNewswire/ -- Transave Inc.

MONMOUTH JUNCTION, N.J., March 31 /PRNewswire/ -- Transave, Inc., a biopharmaceutical company focused on developing innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases today announced that it has raised an aggregate of $35 million pursuant to its recently completed preferred stock offering.